COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.
复制标题
DOI：
10.1016/j.jaci.2020.12.620
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
UK PIN COVID-19 Consortium
中科院分区：
文献类型：
--
作者：
Shields AM;Burns SO;Savic S;Richter AG;UK PIN COVID-19 Consortium
截至2020年11月，严重急性呼吸综合征冠状病毒2已导致全球5,500万人感染，130多万人死于冠状病毒病2019年(新冠肺炎)。严重急性呼吸综合征冠状病毒2型感染在患有原发免疫缺陷(PID)或有症状的继发免疫缺陷(SID)的个体中的结果仍不确定。我们试图记录患有PID或有症状的SID的患者在英国接受新冠肺炎治疗的结果。在新冠肺炎大流行开始时，英国初级免疫缺陷网络建立了一个病例登记处，以整理全国范围内患有PID或有症状的SID的患者的新冠肺炎结果，并确定与这些患者组中新冠肺炎的发病率和死亡率相关的风险因素。截至2020年7月1日，共有100名患者入选，其中60人患有PID，7人患有其他先天免疫缺陷，包括自身炎症性疾病和C1抑制物缺陷，33人患有症状性SID。在PID患者中，53.3%(32/60)住院，感染/病死率20.0%(12/60)，病死率31.6%(12/38)，住院死亡率37.5%(12/32)。SID患者预后较PID患者差，住院治疗占75.8%(25/33)，感染病死率为33.3%(11/33)，病死率为39.2%(11/28)，住院死亡率为44.0%(11/25)。与普通人群相比，患有PID和有症状的SID的成人患者在新冠肺炎中的发病率和死亡率更高。这种增加的风险必须反映在公共卫生指南中，以充分保护易受感染的患者免受病毒感染。
As of November 2020, severe acute respiratory syndrome coronavirus 2 has resulted in 55 million infections worldwide and more than 1.3 million deaths from coronavirus disease 2019 (COVID-19). Outcomes following severe acute respiratory syndrome coronavirus 2 infection in individuals with primary immunodeficiency (PID) or symptomatic secondary immunodeficiency (SID) remain uncertain. We sought to document the outcomes of individuals with PID or symptomatic SID following COVID-19 in the United Kingdom. At the start of the COVID-19 pandemic, the United Kingdom Primary Immunodeficiency Network established a registry of cases to collate the nationwide outcomes of COVID-19 in individuals with PID or symptomatic SID and determine risk factors associated with morbidity and mortality from COVID-19 in these patient groups. A total of 100 patients had been enrolled by July 1, 2020, 60 with PID, 7 with other inborn errors of immunity including autoinflammatory diseases and C1 inhibitor deficiency, and 33 with symptomatic SID. In individuals with PID, 53.3% (32 of 60) were hospitalized, the infection-fatality ratio was 20.0% (12 of 60), the case-fatality ratio was 31.6% (12 of 38), and the inpatient mortality was 37.5% (12 of 32). Individuals with SID had worse outcomes than those with PID; 75.8% (25 of 33) were hospitalized, the infection-fatality ratio was 33.3% (11 of 33), the case-fatality ratio was 39.2% (11 of 28), and inpatient mortality was 44.0% (11 of 25). In comparison to the general population, adult patients with PID and symptomatic SID display greater morbidity and mortality from COVID-19. This increased risk must be reflected in public health guidelines to adequately protect vulnerable patients from exposure to the virus.
登录
查看更多内容
DOI：
10.1016/s1473-3099(20)30243-7
发表时间：
2020-06-01
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Verity, Robert;Okell, Lucy C;Ferguson, Neil M
通讯作者：
Ferguson, Neil M
DOI：
10.1016/j.jaci.2020.09.010
发表时间：
2021-03
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Meyts I;Bucciol G;Quinti I;Neven B;Fischer A;Seoane E;Lopez-Granados E;Gianelli C;Robles-Marhuenda A;Jeandel PY;Paillard C;Sankaran VG;Demirdag YY;Lougaris V;Aiuti A;Plebani A;Milito C;Dalm VA;Guevara-Hoyer K;Sánchez-Ramón S;Bezrodnik L;Barzaghi F;Gonzalez-Granado LI;Hayman GR;Uzel G;Mendonça LO;Agostini C;Spadaro G;Badolato R;Soresina A;Vermeulen F;Bosteels C;Lambrecht BN;Keller M;Mustillo PJ;Abraham RS;Gupta S;Ozen A;Karakoc-Aydiner E;Baris S;Freeman AF;Yamazaki-Nakashimada M;Scheffler-Mendoza S;Espinosa-Padilla S;Gennery AR;Jolles S;Espinosa Y;Poli MC;Fieschi C;Hauck F;Cunningham-Rundles C;Mahlaoui N;IUIS Committee of Inborn Errors of Immunity;Warnatz K;Sullivan KE;Tangye SG
通讯作者：
Tangye SG
影响因子：
105.7
作者：
Docherty, Annemarie B.;Harrison, Ewen M.;Semple, Malcolm G.
通讯作者：
Semple, Malcolm G.
影响因子：
14.2
作者：
Quinti, Isabella;Lougaris, Vassilios;Plebani, Alessandro
通讯作者：
Plebani, Alessandro
影响因子：
64.8
作者：
Williamson EJ;Walker AJ;Bhaskaran K;Bacon S;Bates C;Morton CE;Curtis HJ;Mehrkar A;Evans D;Inglesby P;Cockburn J;McDonald HI;MacKenna B;Tomlinson L;Douglas IJ;Rentsch CT;Mathur R;Wong AYS;Grieve R;Harrison D;Forbes H;Schultze A;Croker R;Parry J;Hester F;Harper S;Perera R;Evans SJW;Smeeth L;Goldacre B
通讯作者：
Goldacre B